On 10 October 2019, Ingrid Klingmann, Chairman of the European Forum for Good Clinical Practice (EFGCP), published a guest blog entry on the website of the European Federation of Pharmaceutical Industries and Associations (EFPIA) entitled “How big is the need for cross-border access to clinical trials?”
Within the entry, the author advocates for the development of a guideline on best practices to cross-border access to clinical trials, which is endorsed by the research consortium that was established by EFPIA in the context of the revision of the cross-border health directive.
In the context of cross-border clinical trials, the guideline on best practises shall:
In regard of the establishment of the new Commission as well as the development of policy priorities for the next five years, the claim for the development of a guideline on best practices to cross-border access to clinical trials by relevant stakeholders in the field of research and healthcare is intended to put the topic on the agenda of relevant EU policymakers.
Full details can be found here